{
  "meta": {
    "title": "67_Heart_Failure",
    "url": "https://brainandscalpel.vercel.app/67-heart-failure-39122f02.html",
    "scrapedAt": "2025-11-30T12:29:00.500Z"
  },
  "questions": [
    {
      "text": "A 48-year-old man presents with tiredness and palpitations. He also complains of abdominal pain, increased frequency of urination at night, and unexplained weight gain. On examination, the pulse is irregular at 118 beats/min. Bilateral pitting pedal edema is present. ECG is suggestive of right axis deviation.  Which of the following feature is unlikely to be present in this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Pulsatile liver"
        },
        {
          "id": 2,
          "text": "Raised right atrial pressure"
        },
        {
          "id": 3,
          "text": "Positive hepatojugular reflux"
        },
        {
          "id": 4,
          "text": "Increased PCWP"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The above scenario is suggestive of<strong> right-sided heart failure</strong><strong>. </strong>Increased PCWP is not a sign of right-sided heart failure. <strong>PCWP</strong> is an indirect measurement of the left atrial pressure. Hence, it is a sign of <strong>left-sided heart failure.</strong></p>\n<p>The signs of heart failure are:</p>\n<table>\n<tbody>\n<tr>\n<td>Right heart failure</td>\n<td>Left heart failure</td>\n</tr>\n<tr>\n<td>Due to <strong>congestion</strong> in the <strong>systemic circulation</strong></td>\n<td>Due to&nbsp;<strong>congestion</strong> in the <strong>lungs.</strong>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Symptoms and signs:</p>\n<ul>\n<li>Raised JVP</li>\n<li>Congestive hepatomegaly</li>\n<li>Positive hepatojugular reflux</li>\n<li>Ascites</li>\n<li>Bilateral pitting edema&nbsp;</li>\n<li>Weight gain- due to edema</li>\n<li>Fatigue- due to&nbsp;&darr;pumping of blood to lungs leading to&nbsp;&darr;oxygenation of the blood</li>\n</ul>\n</td>\n<td>\n<p>Symptoms and signs:&nbsp;</p>\n<ul>\n<li>Dyspnea on exertion</li>\n<li>Orthopnea</li>\n<li>Paroxysmal nocturnal dyspnea (characteristic of LVF)</li>\n<li>Pulmonary rales&nbsp;</li>\n<li>Increased PCWP</li>\n<li>Fatigue- due to&nbsp;&darr;cardiac output</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8731",
      "difficulty": "medium"
    },
    {
      "text": "A patient who is being evaluated for heart failure undergoes echocardiography for assessment of ejection fraction (EF). When will you categorize his condition as heart failure with reduced ejection fraction based on the results?",
      "choices": [
        {
          "id": 1,
          "text": "EF < 30%"
        },
        {
          "id": 2,
          "text": "EF < 40%"
        },
        {
          "id": 3,
          "text": "EF < 50%"
        },
        {
          "id": 4,
          "text": "EF < 60%"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Heart failure with<strong> reduced ejection fraction </strong>is ejection fraction<strong>&nbsp;&lt;40%.</strong></p>\n<p>According to the European society of cardiology (ESC) heart failure guidelines 2016 -</p>\n<ul>\n<li>Heart failure with reduced ejection fraction (HFrEF)- ejection fraction &lt;40%</li>\n<li>Heart failure with <strong>mid-range ejection Fraction</strong> (HFmrEF)- ejection fraction&nbsp;<strong>40-50%</strong></li>\n<li>Heart failure with preserved ejection fraction (HFpEF)-<strong><strong>&nbsp;</strong></strong>ejection fraction &gt;50%</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8728",
      "difficulty": "easy"
    },
    {
      "text": "A 65-year-old male patient came with complaints of episodes of shortness of breath and coughing at night which awakens him from sleep. On examination, distended neck veins were observed and S3 was heard on auscultation. Which of the following biomarkers can be used for the diagnosis in this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Brain natriuretic peptide (BNP)"
        },
        {
          "id": 2,
          "text": "Atrial natriuretic peptide (ANP)"
        },
        {
          "id": 3,
          "text": "Endothelin-1 (ET-1)"
        },
        {
          "id": 4,
          "text": "Lipocalin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given clinical scenario suggests a diagnosis of <strong>heart failure. </strong>The&nbsp;brain natriuretic peptide<strong> (BNP</strong>) can be used to confirm this.</p>\n<p><strong>Natriuretic</strong> <strong>peptides</strong> are protein molecules that are secreted by the ventricular <strong>myocytes</strong> in response to volume or pressure overload. Ventricular musculature releases pre-proBNP which is cleaved into active BNP and inert NT-proBNP.</p>\n<p>BNP causes natriuresis, vasodilatation, and diuresis that leads to improved<strong> myocardial relaxation.</strong>&nbsp; These peptides also counteract the actions of the renin-angiotensin-aldosterone system.&nbsp;<span>Measurement of both <strong>BNP </strong>and inert<strong> NT-proBNP</strong> levels can be used in the <strong>diagnosis </strong>of heart failure and to determine the <strong>prognosis.</strong></span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1616",
      "difficulty": "medium"
    },
    {
      "text": "Falsely low values of BNP can be seen in which of the following?",
      "choices": [
        {
          "id": 1,
          "text": "Advanced age"
        },
        {
          "id": 2,
          "text": "Female patients"
        },
        {
          "id": 3,
          "text": "Obesity"
        },
        {
          "id": 4,
          "text": "Renal impairment"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Falsely low</strong> values of<strong> BNP</strong> can be seen in <strong>obese</strong> patients.</p>\n<p>It is also falsely <strong>low</strong> in:</p>\n<ul>\n<li>Flash pulmonary edema</li>\n<li>Heart failure due to- mitral regurgitation, mitral stenosis, constrictive pericarditis, restrictive cardiomyopathy</li>\n</ul>\n<p>It falsely <strong>increases</strong> in:</p>\n<ul>\n<li>Advanced age</li>\n<li>Renal impairment</li>\n<li>Female patients</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8725",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is a newer biomarker to assess the prognosis in a patient with heart failure?",
      "choices": [
        {
          "id": 1,
          "text": "Soluble ST-2"
        },
        {
          "id": 2,
          "text": "Lipocalin"
        },
        {
          "id": 3,
          "text": "Endothelin-1 (ET-1)"
        },
        {
          "id": 4,
          "text": "Cystatin C"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Soluble ST-2</strong>&nbsp;is a&nbsp;newer biomarker that can be used for determining the <strong>prognosis</strong> of patients with<strong> heart failure</strong>. Other newer biomarkers used are&nbsp; <strong>g</strong><strong>alectin-3, GDF 15</strong>.&nbsp;</p>\n<p>Options B and D:<strong> Lipocalin</strong>, also known as neutrophil gelatinase-associated lipocalin (<strong>NGAL</strong>) or siderocalin, <strong>cystatin C</strong>, and IL-18 are biomarkers of acute kidney injury (<strong>AKI</strong>).</p>\n<p>Option C: <strong>Endothelin-1</strong> is a useful biomarker for&nbsp;early detection of bronchiolitis obliterans in <strong>lung transplant recipients</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8730",
      "difficulty": "medium"
    },
    {
      "text": "A patient is diagnosed with heart failure with an ejection fraction < 40%. What is the treatment of choice in this patient after the euvolemic status has been achieved?",
      "choices": [
        {
          "id": 1,
          "text": "ARBs + Diuretics"
        },
        {
          "id": 2,
          "text": "ACE inhibitors + Beta-blockers"
        },
        {
          "id": 3,
          "text": "CCBs + ARBs"
        },
        {
          "id": 4,
          "text": "Diuretics + CCBs"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>ACE inhibitors + beta-blockers</strong> are the treatment of choice in patients with heart failure with an ejection fraction of &lt;40% after euvolemic status is achieved using diuretics.</p>\n<p>The <strong>first-line drugs</strong> used in congestive heart failure with reduced ejection fraction are<strong> ACE inhibitors + diuretics</strong>. Once the euvolemic status is achieved, ACE inhibitors + beta-blockers are<strong>&nbsp;</strong>the drugs of choice.</p>\n<p>Beta-blockers&nbsp;that improve survival in heart failure with reduced ejection fraction are carvedilol, metoprolol, and bisoprolol.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1640",
      "difficulty": "medium"
    },
    {
      "text": "The preferred drug for a patient with chronic symptomatic heart failure with reduced ejection fraction is:",
      "choices": [
        {
          "id": 1,
          "text": "Bosentan"
        },
        {
          "id": 2,
          "text": "Sacubitril/Valsartan"
        },
        {
          "id": 3,
          "text": "Omapatrilat"
        },
        {
          "id": 4,
          "text": "Moxonidine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Sacubitril/Valsartan</strong>, an&nbsp;<strong>angiotensin receptor neprilysin inhibitor&nbsp;</strong>(ARNI), is used in patients with chronic symptomatic HFrEF to <strong>reduce morbidity</strong> and <strong>mortality</strong> (class I recommendation).&nbsp;</p>\n<p>Sacubitril (neprilysin inhibitor) is approved in combination with valsartan (ARB), in a ratio of 1:1. The combination is approved for use in <strong>chronic heart failure.</strong></p>\n<div>Sacubitril is a <strong>prodrug</strong> that is activated to sacubitrilat. It inhibits the enzyme neprilysin (neutral endopeptidase),&nbsp;which is responsible for the degradation of atrial and brain natriuretic peptides (reduction of blood volume). Thus, it increases the levels of atrial and brain natriuretic peptides and lowers blood pressure.</div><p><strong>Vericiguat</strong>, an oral <strong>soluble guanylate cyclase stimulator</strong> has been approved by FDA for the treatment of chronic HFrEF. It leads to smooth muscle relaxation and vasodilation.&nbsp;</p><hr><h3>Related Pearl: Drugs used in heart failure</h3><div>Drugs used in<strong> acute decompensated heart failure:</strong></div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous vasodilators</strong></td>\n</tr>\n<tr>\n<td>\n<p>Nitroglycerine</p>\n<p>Sodium nitroprusside</p>\n</td>\n<td>Decrease preload and afterload</td>\n</tr>\n<tr>\n<td>Nesiritide</td>\n<td>Recombinant human BNP</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous positive inotropes</strong></td>\n</tr>\n<tr>\n<td>\n<p>Dobutamine</p>\n<p>Dopamine</p>\n<p>Epinephrine</p>\n<p>Norepinephrine</p>\n</td>\n<td>&beta;1 receptor-mediated stimulation of cardiac output</td>\n</tr>\n<tr>\n<td>\n<p>Enoximone</p>\n<p>Milrinone</p>\n</td>\n<td>PDE 3/4 inhibitors</td>\n</tr>\n<tr>\n<td>\n<p>Levosimendan</p>\n<p>Pimobendan</p>\n</td>\n<td>Combined Ca<sup>2+</sup> sensitizers and PDE3 inhibitors</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Drugs used for rapid symptom relief</strong></td>\n</tr>\n<tr>\n<td>\n<p>Bumetanide</p>\n<p>Furosemide</p>\n<p>Torasemide</p>\n</td>\n<td>Loop diuretics- used for symptomatic treatment of severe heart failure and acute decompensation.</td>\n</tr>\n<tr>\n<td>Morphine</td>\n<td>Opioid - to calm the patient and decreases cardiac O2 consumption</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>Drugs used in<strong> chronic heart failure:</strong></div>\n<div>\n<table>\n<tbody>\n<tr>\n<td><strong>Drugs</strong></td>\n<td><strong>Uses</strong></td>\n</tr>\n<tr>\n<td>ACE inhibitors</td>\n<td>Used as first-line therapy</td>\n</tr>\n<tr>\n<td>ARBs</td>\n<td>Used in case of intolerance to ACE inhibitors</td>\n</tr>\n<tr>\n<td>Beta-blockers</td>\n<td>Used as first-line therapy &nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Spironolactone</p>\n<p>Eplerenone</p>\n</td>\n<td>Mineralocorticoid receptor antagonists - first-line drugs for symptomatic heart failure.</td>\n</tr>\n<tr>\n<td>SGLT-2 inhibitors</td>\n<td>Used as 1st line therapy- reduces mortality and morbidity</td>\n</tr>\n<tr>\n<td>Sacubitril/Valsartan</td>\n<td>Neprilysin inhibitor/ARB(ARNI)</td>\n</tr>\n<tr>\n<td>Ivabradine</td>\n<td>Inhibitor of I<sub>f</sub>&nbsp;current in the sinoatrial node</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8762",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following drugs is a selective myosin activator?",
      "choices": [
        {
          "id": 1,
          "text": "Istaroxime"
        },
        {
          "id": 2,
          "text": "Omecamtiv mecarbil"
        },
        {
          "id": 3,
          "text": "Carperitide"
        },
        {
          "id": 4,
          "text": "Milrinone"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Omecamtiv mecarbil</strong> is the <strong>selective myosin activator</strong>. It&nbsp;activates cardiac myosin and prolongs systole without increasing oxygen consumption of the heart.</p><p>It is still <strong>pending</strong> FDA approval for use in patients with heart failure with reduced ejection fraction.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8758",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs used in heart failure is an inhibitor of I(f) current in the sinoatrial node ?",
      "choices": [
        {
          "id": 1,
          "text": "Omapatrilat"
        },
        {
          "id": 2,
          "text": "Ivabradine"
        },
        {
          "id": 3,
          "text": "Nesiritide"
        },
        {
          "id": 4,
          "text": "Levosimendan"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Ivabradine</strong> is an <strong>inhibitor of I<sub><em>f&nbsp;</em></sub>current </strong>in the<strong> sinoatrial node. </strong>It&nbsp;reduces the heart rate without decreasing the force of contraction.</p>\n<p>It is used in patients with <strong>chronic HFrEF</strong> with a sinus rhythm and a <strong>resting heart rate &ge;70 </strong>bpm who are either on a maximum tolerated beta-blocker dose or have a contraindication for beta-blockers. The concurrent treatment should include ACE inhibitor ( or ARB ) and aldosterone receptor antagonist.</p>\n<p>Option A:&nbsp;Omapatrilat&nbsp;is a&nbsp;dual neprilysin inhibitor+ ACE inhibitor.</p>\n<p>Option C: Nesiritide belongs to the intravenous vasodilators class and is a&nbsp;recombinant human brain natriuretic peptide (BNP).&nbsp;</p>\n<p>Option D: Levosimendan belongs to the positive inotropes class and is a combined calcium sensitizer and PDE3 inhibitor.&nbsp;</p><hr><h3>Related Pearl: Drugs used in heart failure</h3><div>Drugs used in<strong> acute decompensated heart failure:</strong></div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous vasodilators</strong></td>\n</tr>\n<tr>\n<td>\n<p>Nitroglycerine</p>\n<p>Sodium nitroprusside</p>\n</td>\n<td>Decrease preload and afterload</td>\n</tr>\n<tr>\n<td>Nesiritide</td>\n<td>Recombinant human BNP</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous positive inotropes</strong></td>\n</tr>\n<tr>\n<td>\n<p>Dobutamine</p>\n<p>Dopamine</p>\n<p>Epinephrine</p>\n<p>Norepinephrine</p>\n</td>\n<td>&beta;1 receptor-mediated stimulation of cardiac output</td>\n</tr>\n<tr>\n<td>\n<p>Enoximone</p>\n<p>Milrinone</p>\n</td>\n<td>PDE 3/4 inhibitors</td>\n</tr>\n<tr>\n<td>\n<p>Levosimendan</p>\n<p>Pimobendan</p>\n</td>\n<td>Combined Ca<sup>2+</sup> sensitizers and PDE3 inhibitors</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Drugs used for rapid symptom relief</strong></td>\n</tr>\n<tr>\n<td>\n<p>Bumetanide</p>\n<p>Furosemide</p>\n<p>Torasemide</p>\n</td>\n<td>Loop diuretics- used for symptomatic treatment of severe heart failure and acute decompensation.</td>\n</tr>\n<tr>\n<td>Morphine</td>\n<td>Opioid - to calm the patient and decreases cardiac O2 consumption</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>Drugs used in<strong> chronic heart failure:</strong></div>\n<div>\n<table>\n<tbody>\n<tr>\n<td><strong>Drugs</strong></td>\n<td><strong>Uses</strong></td>\n</tr>\n<tr>\n<td>ACE inhibitors</td>\n<td>Used as first-line therapy</td>\n</tr>\n<tr>\n<td>ARBs</td>\n<td>Used in case of intolerance to ACE inhibitors</td>\n</tr>\n<tr>\n<td>Beta-blockers</td>\n<td>Used as first-line therapy &nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Spironolactone</p>\n<p>Eplerenone</p>\n</td>\n<td>Mineralocorticoid receptor antagonists - first-line drugs for symptomatic heart failure.</td>\n</tr>\n<tr>\n<td>SGLT-2 inhibitors</td>\n<td>Used as 1st line therapy- reduces mortality and morbidity</td>\n</tr>\n<tr>\n<td>Sacubitril/Valsartan</td>\n<td>Neprilysin inhibitor/ARB(ARNI)</td>\n</tr>\n<tr>\n<td>Ivabradine</td>\n<td>Inhibitor of I<sub>f</sub>&nbsp;current in the sinoatrial node</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8766",
      "difficulty": "easy"
    },
    {
      "text": "In a patient with heart failure, which of the following is not used as an inotropic agent?",
      "choices": [
        {
          "id": 1,
          "text": "Levosimendan"
        },
        {
          "id": 2,
          "text": "Milrinone"
        },
        {
          "id": 3,
          "text": "Omecamtiv Mecarbil"
        },
        {
          "id": 4,
          "text": "Nesiritide"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Nesiritide </strong>is not used as an inotropic agent. It belongs to the<strong> intravenous vasodilator</strong> class and is a recombinant brain natriuretic peptide (<strong>BNP</strong>)</p>\n<p>Option A: Levosimendan belongs to the positive inotropes class and is a combined calcium sensitizer and PDE3 inhibitor.</p>\n<p>Option B: Milrinone belongs to the positive inotrope class and is a PDE-3/4 inhibitor.</p>\n<p>Option C: Omecamtiv mecarbil is a&nbsp;selective myosin activator that increases myocardial contractility without increasing the myocardial oxygen demand.</p><hr><h3>Related Pearl: Drugs used in heart failure</h3><div>Drugs used in<strong> acute decompensated heart failure:</strong></div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous vasodilators</strong></td>\n</tr>\n<tr>\n<td>\n<p>Nitroglycerine</p>\n<p>Sodium nitroprusside</p>\n</td>\n<td>Decrease preload and afterload</td>\n</tr>\n<tr>\n<td>Nesiritide</td>\n<td>Recombinant human BNP</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous positive inotropes</strong></td>\n</tr>\n<tr>\n<td>\n<p>Dobutamine</p>\n<p>Dopamine</p>\n<p>Epinephrine</p>\n<p>Norepinephrine</p>\n</td>\n<td>&beta;1 receptor-mediated stimulation of cardiac output</td>\n</tr>\n<tr>\n<td>\n<p>Enoximone</p>\n<p>Milrinone</p>\n</td>\n<td>PDE 3/4 inhibitors</td>\n</tr>\n<tr>\n<td>\n<p>Levosimendan</p>\n<p>Pimobendan</p>\n</td>\n<td>Combined Ca<sup>2+</sup> sensitizers and PDE3 inhibitors</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Drugs used for rapid symptom relief</strong></td>\n</tr>\n<tr>\n<td>\n<p>Bumetanide</p>\n<p>Furosemide</p>\n<p>Torasemide</p>\n</td>\n<td>Loop diuretics- used for symptomatic treatment of severe heart failure and acute decompensation.</td>\n</tr>\n<tr>\n<td>Morphine</td>\n<td>Opioid - to calm the patient and decreases cardiac O2 consumption</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>Drugs used in<strong> chronic heart failure:</strong></div>\n<div>\n<table>\n<tbody>\n<tr>\n<td><strong>Drugs</strong></td>\n<td><strong>Uses</strong></td>\n</tr>\n<tr>\n<td>ACE inhibitors</td>\n<td>Used as first-line therapy</td>\n</tr>\n<tr>\n<td>ARBs</td>\n<td>Used in case of intolerance to ACE inhibitors</td>\n</tr>\n<tr>\n<td>Beta-blockers</td>\n<td>Used as first-line therapy &nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Spironolactone</p>\n<p>Eplerenone</p>\n</td>\n<td>Mineralocorticoid receptor antagonists - first-line drugs for symptomatic heart failure.</td>\n</tr>\n<tr>\n<td>SGLT-2 inhibitors</td>\n<td>Used as 1st line therapy- reduces mortality and morbidity</td>\n</tr>\n<tr>\n<td>Sacubitril/Valsartan</td>\n<td>Neprilysin inhibitor/ARB(ARNI)</td>\n</tr>\n<tr>\n<td>Ivabradine</td>\n<td>Inhibitor of I<sub>f</sub>&nbsp;current in the sinoatrial node</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8770",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following beta-blockers would you prefer to use in a patient with heart failure with reduced ejection fraction?",
      "choices": [
        {
          "id": 1,
          "text": "Atenolol"
        },
        {
          "id": 2,
          "text": "Nebivolol"
        },
        {
          "id": 3,
          "text": "Esmolol"
        },
        {
          "id": 4,
          "text": "Bisoprolol"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Bisoprolol</strong> is preferred for use in patients having heart failure with reduced ejection fraction (HFrEF).</p>\n<p>The only beta-blockers that have been proved to improve the survival of patients with HFrEF or chronic HF are -</p>\n<ul>\n<li><strong>B</strong>isoprolol</li>\n<li><strong>M</strong>etoprolol</li>\n<li><strong>C</strong>arvedilol</li>\n</ul>\n<p>Note: Nebivolol is not approved by FDA for the treatment of heart failure.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8764",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following drugs does not reduce mortality in a patient with heart failure with reduced ejection fraction?",
      "choices": [
        {
          "id": 1,
          "text": "Digoxin"
        },
        {
          "id": 2,
          "text": "Beta-blockers"
        },
        {
          "id": 3,
          "text": "ACE inhibitors"
        },
        {
          "id": 4,
          "text": "Hydralazine + Isosorbide dinitrate"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Digoxin does not reduce mortality in patients with HFrEF.</p>\n<p>The drugs which <strong>reduce</strong> <strong>mortality</strong> in patients with <strong>HFrEF</strong> are :</p>\n<ul>\n<li><strong>ACE inhibitors</strong></li>\n<li>Angiotensin receptor blockers (ARBs)</li>\n<li>Angiotensin receptor neprilysin inhibitor (ARNI)</li>\n<li><strong>Beta-blockers</strong></li>\n<li>Aldosterone antagonists\n<ul>\n<li>Spironolactone</li>\n<li>Eplerenone</li>\n</ul>\n</li>\n<li><strong>Hydralazine+Nitrates</strong></li>\n</ul><hr><h3>Related Pearl: Drugs used in heart failure</h3><div>Drugs used in<strong> acute decompensated heart failure:</strong></div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous vasodilators</strong></td>\n</tr>\n<tr>\n<td>\n<p>Nitroglycerine</p>\n<p>Sodium nitroprusside</p>\n</td>\n<td>Decrease preload and afterload</td>\n</tr>\n<tr>\n<td>Nesiritide</td>\n<td>Recombinant human BNP</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous positive inotropes</strong></td>\n</tr>\n<tr>\n<td>\n<p>Dobutamine</p>\n<p>Dopamine</p>\n<p>Epinephrine</p>\n<p>Norepinephrine</p>\n</td>\n<td>&beta;1 receptor-mediated stimulation of cardiac output</td>\n</tr>\n<tr>\n<td>\n<p>Enoximone</p>\n<p>Milrinone</p>\n</td>\n<td>PDE 3/4 inhibitors</td>\n</tr>\n<tr>\n<td>\n<p>Levosimendan</p>\n<p>Pimobendan</p>\n</td>\n<td>Combined Ca<sup>2+</sup> sensitizers and PDE3 inhibitors</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Drugs used for rapid symptom relief</strong></td>\n</tr>\n<tr>\n<td>\n<p>Bumetanide</p>\n<p>Furosemide</p>\n<p>Torasemide</p>\n</td>\n<td>Loop diuretics- used for symptomatic treatment of severe heart failure and acute decompensation.</td>\n</tr>\n<tr>\n<td>Morphine</td>\n<td>Opioid - to calm the patient and decreases cardiac O2 consumption</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>Drugs used in<strong> chronic heart failure:</strong></div>\n<div>\n<table>\n<tbody>\n<tr>\n<td><strong>Drugs</strong></td>\n<td><strong>Uses</strong></td>\n</tr>\n<tr>\n<td>ACE inhibitors</td>\n<td>Used as first-line therapy</td>\n</tr>\n<tr>\n<td>ARBs</td>\n<td>Used in case of intolerance to ACE inhibitors</td>\n</tr>\n<tr>\n<td>Beta-blockers</td>\n<td>Used as first-line therapy &nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Spironolactone</p>\n<p>Eplerenone</p>\n</td>\n<td>Mineralocorticoid receptor antagonists - first-line drugs for symptomatic heart failure.</td>\n</tr>\n<tr>\n<td>SGLT-2 inhibitors</td>\n<td>Used as 1st line therapy- reduces mortality and morbidity</td>\n</tr>\n<tr>\n<td>Sacubitril/Valsartan</td>\n<td>Neprilysin inhibitor/ARB(ARNI)</td>\n</tr>\n<tr>\n<td>Ivabradine</td>\n<td>Inhibitor of I<sub>f</sub>&nbsp;current in the sinoatrial node</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8763",
      "difficulty": "medium"
    },
    {
      "text": "A 45-year-old female patient has NYHA class III heart failure with dyspnea, pedal edema and K+ levels of 5.5 mg% and creatinine 1.1 mg%. Which of the following drugs can be used in this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Digoxin"
        },
        {
          "id": 2,
          "text": "Spironolactone"
        },
        {
          "id": 3,
          "text": "Enalapril"
        },
        {
          "id": 4,
          "text": "Furosemide"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The clinical scenario describes a patient with <strong>symptomatic heart failure</strong> and&nbsp;<strong>K<sup>+ </sup>levels of 5.5 mg%</strong>. She requires a diuretic for symptom control. <strong>Furosemide&nbsp;</strong>can be given safely as it causes <strong>hypokalemia.</strong></p>\n<p>Other options:</p>\n<p>Option A:&nbsp;<strong>Digoxin</strong> is not used as a first-line drug in the management of symptomatic heart failure.</p>\n<p>Options B and C:&nbsp;<strong>Spironolactone</strong> (K<sup>+ </sup>sparing diuretic) and <strong>enalapril</strong> (ACE inhibitor) can cause hyperkalemia.&nbsp;&nbsp;</p>\n<p>The first step in managing acute decompensated heart failure (ADHF) is addressing the factors that caused the decompensation. They include&nbsp;<strong>nonadherence</strong> to medications, dietary indiscretion, medication use that exacerbates heart failure, <strong>coronary ischemia</strong>, <strong>arrhythmias</strong>, valvular heart disease, <strong>infection</strong>, and pulmonary <strong>thromboembolism</strong>.</p>\n<p><strong>Volume management</strong> is crucial in ADHF. Intravenous <strong>loop diuretics</strong> are used to relieve congestion. The effectiveness of diuretic therapy can be assessed by changes in weight, improvement in symptoms, and clinical examination findings. <strong>Natriuretic peptide</strong> levels can also help assess the adequacy of therapy and predict risk.</p>\n<p><strong>Cardiorenal syndrome</strong>, characterized by the interplay between heart and kidney dysfunction, is a common complication of ADHF. Diuretic therapy should be carefully managed to avoid worsening renal function in patients with elevated right-sided filling pressures. In cases of severe low cardiac output, inotropic therapy or mechanical circulatory support may be necessary to preserve or improve renal function temporarily.</p>\n<p><strong>Vasodilators</strong> like nitroglycerin, sodium nitroprusside, and <strong>nesiritide&nbsp;</strong>(recombinant BNP) are used to reduce filling pressures and systemic vascular resistance.&nbsp;</p>\n<p><strong>Inotropic therapy</strong> with drugs like <strong>dopamine</strong> and <strong>milrinone</strong> is used to increase myocardial contractility and improve cardiac output in patients with <strong>low-output</strong> ADHF. Dopamine has dose-dependent effects on different receptors, while milrinone is a phosphodiesterase-3 inhibitor.</p><hr><h3>Related Pearl: Drugs used in heart failure</h3><div>Drugs used in<strong> acute decompensated heart failure:</strong></div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous vasodilators</strong></td>\n</tr>\n<tr>\n<td>\n<p>Nitroglycerine</p>\n<p>Sodium nitroprusside</p>\n</td>\n<td>Decrease preload and afterload</td>\n</tr>\n<tr>\n<td>Nesiritide</td>\n<td>Recombinant human BNP</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Intravenous positive inotropes</strong></td>\n</tr>\n<tr>\n<td>\n<p>Dobutamine</p>\n<p>Dopamine</p>\n<p>Epinephrine</p>\n<p>Norepinephrine</p>\n</td>\n<td>&beta;1 receptor-mediated stimulation of cardiac output</td>\n</tr>\n<tr>\n<td>\n<p>Enoximone</p>\n<p>Milrinone</p>\n</td>\n<td>PDE 3/4 inhibitors</td>\n</tr>\n<tr>\n<td>\n<p>Levosimendan</p>\n<p>Pimobendan</p>\n</td>\n<td>Combined Ca<sup>2+</sup> sensitizers and PDE3 inhibitors</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Drugs used for rapid symptom relief</strong></td>\n</tr>\n<tr>\n<td>\n<p>Bumetanide</p>\n<p>Furosemide</p>\n<p>Torasemide</p>\n</td>\n<td>Loop diuretics- used for symptomatic treatment of severe heart failure and acute decompensation.</td>\n</tr>\n<tr>\n<td>Morphine</td>\n<td>Opioid - to calm the patient and decreases cardiac O2 consumption</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>\n<div>Drugs used in<strong> chronic heart failure:</strong></div>\n<div>\n<table>\n<tbody>\n<tr>\n<td><strong>Drugs</strong></td>\n<td><strong>Uses</strong></td>\n</tr>\n<tr>\n<td>ACE inhibitors</td>\n<td>Used as first-line therapy</td>\n</tr>\n<tr>\n<td>ARBs</td>\n<td>Used in case of intolerance to ACE inhibitors</td>\n</tr>\n<tr>\n<td>Beta-blockers</td>\n<td>Used as first-line therapy &nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Spironolactone</p>\n<p>Eplerenone</p>\n</td>\n<td>Mineralocorticoid receptor antagonists - first-line drugs for symptomatic heart failure.</td>\n</tr>\n<tr>\n<td>SGLT-2 inhibitors</td>\n<td>Used as 1st line therapy- reduces mortality and morbidity</td>\n</tr>\n<tr>\n<td>Sacubitril/Valsartan</td>\n<td>Neprilysin inhibitor/ARB(ARNI)</td>\n</tr>\n<tr>\n<td>Ivabradine</td>\n<td>Inhibitor of I<sub>f</sub>&nbsp;current in the sinoatrial node</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n<div>&nbsp;</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9413",
      "difficulty": "medium"
    },
    {
      "text": "A patient was brought to the emergency with dyspnea, cough, and chest pain. His blood pressure was 180/100 mmHg and SpO2 was 90%. Chest X-ray is shown below. Echocardiography revealed reduced LV ejection fraction (LVEF). Which of the following will you not use in the management of this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Digoxin"
        },
        {
          "id": 2,
          "text": "Morphine"
        },
        {
          "id": 3,
          "text": "Furosemide"
        },
        {
          "id": 4,
          "text": "Positive pressure ventilation"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The above X-ray showing <strong>batwing appearance</strong> along with the given symptoms and <strong>reduced LVEF</strong> is suggestive of <strong>acute decompensated heart failure&nbsp;</strong>with <strong>pulmonary edema</strong>. Digoxin has no role in the management of this condition.</p>\n<p>The <strong>management</strong> of acute cardiogenic pulmonary edema consists of:</p>\n<ul>\n<li>Oxygen therapy and positive pressure ventilation</li>\n<li>Reduction of preload:\n<ul>\n<li><strong>Diuretics:</strong> Furosemide is the diuretic of choice</li>\n<li><strong>Nitrates</strong>: sublingual nitroglycerin is the<strong> first-line therapy</strong>. If pulmonary edema persists, IV nitroglycerin is administered.</li>\n<li><strong>Morphine</strong>: It is a transient venodilator that reduces preload, thereby reducing dyspnea and anxiety.</li>\n<li><strong>ACE inhibitors</strong>: They reduce both preload and afterload and are recommended for hypertensive patients.</li>\n<li><strong>Nesiritide</strong>: It is an IV recombinant BNP which is a potent vasodilator with diuretic properties.</li>\n<li><strong>Inotropic</strong> and <strong>inodilators:</strong>\n<ul>\n<li>Dopamine, dobutamine-inotropic agents.</li>\n<li>Milrinone- stimulates myocardial contractility and promotes peripheral vasodilatation.</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Intra-aortic balloon counterpulsation- or LV assist devices are used in cardiogenic shock and end-organ failure.</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/c24e386a910e45c4b62dd6d210fb536e.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1620",
      "difficulty": "medium"
    },
    {
      "text": "A patient presents with abrupt worsening of renal function leading to acute cardiac disorder. Which type of cardiorenal syndrome would this be?",
      "choices": [
        {
          "id": 1,
          "text": "Type I"
        },
        {
          "id": 2,
          "text": "Type II"
        },
        {
          "id": 3,
          "text": "Type III"
        },
        {
          "id": 4,
          "text": "Type V"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Type III</strong> cardiorenal syndrome is an abrupt worsening of renal function leading to acute cardiac disorder.</p>\n<p>Cardiorenal Syndrome (CRS): A pathophysiologic disorder of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in the other organ.</p>\n<p><strong>Types of Cardiorenal Syndromes</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Type</strong></p>\n</td>\n<td>\n<p><strong>Precipitating event</strong></p>\n</td>\n<td>\n<p><strong>Resulting in</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>CRS Type I</p>\n<p>(Acute Cardiorenal Syndrome)</p>\n</td>\n<td>\n<p><span dir=\"ltr\" role=\"presentation\">Abrupt worsening of </span><br role=\"presentation\" /><span dir=\"ltr\" role=\"presentation\">cardiac function:</span></p>\n<ul>\n<li><span dir=\"ltr\" role=\"presentation\">Acute cardiogenic </span><br role=\"presentation\" /><span dir=\"ltr\" role=\"presentation\">shock</span></li>\n<li><span dir=\"ltr\" role=\"presentation\">Decompensated </span><br role=\"presentation\" /><span dir=\"ltr\" role=\"presentation\">congestive heart failure</span></li>\n</ul>\n</td>\n<td>Acute kidney injury&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>CRS Type II</p>\n<p>(Chronic Cardiorenal Syndrome)</p>\n</td>\n<td>\n<p><span dir=\"ltr\" role=\"presentation\">Chronic abnormalities in </span><br role=\"presentation\" /><span dir=\"ltr\" role=\"presentation\">cardiac function:</span></p>\n<ul>\n<li>Chronic congestive heart failure</li>\n</ul>\n</td>\n<td>Chronic kidney disease&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>CRS Type III</p>\n<p>(Acute Renocardiac Syndrome)</p>\n</td>\n<td>\n<p>Acute renal dysfunction:</p>\n<ul>\n<li><span dir=\"ltr\" role=\"presentation\">Renal ischemia or </span><br role=\"presentation\" /><span dir=\"ltr\" role=\"presentation\">glomerulonephritis</span></li>\n</ul>\n</td>\n<td>Acute cardiac disorder&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>CRS Type IV</p>\n<p>(Chronic Renocardiac Syndrome)</p>\n</td>\n<td>\n<p>Chronic kidney disease:</p>\n<ul>\n<li>Glomerular disease</li>\n</ul>\n</td>\n<td>\n<p><span dir=\"ltr\" role=\"presentation\">Decreased cardiac </span><br role=\"presentation\" /><span dir=\"ltr\" role=\"presentation\">function</span></p>\n<p><br role=\"presentation\" /><span dir=\"ltr\" role=\"presentation\">Cardiac hypertrophy</span></p>\n<p><br role=\"presentation\" /><span dir=\"ltr\" role=\"presentation\">High risk of adverse </span><br role=\"presentation\" /><span dir=\"ltr\" role=\"presentation\">cardiovascular events</span>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>CRS Type V</p>\n<p>(Secondary Cardiorenal Syndrome)</p>\n</td>\n<td>\n<p>Systemic conditions:</p>\n<ul>\n<li>Diabetes</li>\n<li>Sepsis</li>\n</ul>\n</td>\n<td>Cardiac and renal dysfunction</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA8753",
      "difficulty": "hard"
    },
    {
      "text": "Who comes under category III non-heart-beating donor?",
      "choices": [
        {
          "id": 1,
          "text": "A patient who died during transportation to the hospital"
        },
        {
          "id": 2,
          "text": "A patient who died after failed resuscitation after reaching the hospital"
        },
        {
          "id": 3,
          "text": "A patient who was brought dead to the hospital"
        },
        {
          "id": 4,
          "text": "A patient who is awaiting death in the hospital"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Category III donors</strong> are patients&nbsp;with <strong>non-survivable injuries</strong> who have their <strong>treatment withdrawn</strong> and if such patients wished in life to be <strong>organ donors</strong>, the transplant team can attend at the time of treatment withdrawal and <strong>retrieve organs after cardiac arrest</strong> has occurred.</p>\n<p><strong>Modified Maastricht classification</strong>- Categories of non-heart-beating donors:</p>\n<div id=\"__sec3\" class=\"sec sec-last\">\n<p class=\"p p-last\">&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td>Category</td>\n<td>Description</td>\n<td>Circumstances</td>\n</tr>\n<tr>\n<td>Category I</td>\n<td>Includes <strong>victims of accident and suicide</strong> who are<strong> found dead at the scene</strong> and resuscitation is deemed pointless (e.g. fatal cervical spine fracture).</td>\n<td>Uncontrolled - transplant team not present or prepared&nbsp;</td>\n</tr>\n<tr>\n<td>Category II</td>\n<td><strong>victims of sudden cardiac or cerebral catastrophe</strong> who are brought to emergency departments while being resuscitated by ambulance personnel or who <strong>died in the department</strong>. Other sources include patients suffering an isolated brain injury, anoxia, and stroke, and victims of major trauma who died soon after hospital admission.</td>\n<td>\n<div id=\"__sec2\" class=\"sec sec-first\">&nbsp;</div>\n<div id=\"__sec3\" class=\"sec sec-last\">Uncontrolled - transplant team not present or prepared&nbsp; &nbsp;&nbsp;</div>\n&nbsp;</td>\n</tr>\n<tr>\n<td>Category III</td>\n<td>Patients who are dying, often in an intensive care unit. These are the patients awaiting cardiac arrest where the treating clinicians have decided to withdraw treatment and not commence resuscitation for various reasons.</td>\n<td>\n<div id=\"__sec2\" class=\"sec sec-first\">\n<p class=\"p p-last\">Controlled - transplant team present and prepared</p>\n</div>\n<div id=\"__sec3\" class=\"sec sec-last\">&nbsp;</div>\n&nbsp;</td>\n</tr>\n<tr>\n<td>Category IV</td>\n<td>Comprises patients who suffer <strong>unexpected cardiac arrest</strong> during or after the determination of <strong>brain death.</strong></td>\n<td>\n<div id=\"__sec2\" class=\"sec sec-first\">\n<p class=\"p p-last\">Controlled - transplant team present and prepared</p>\n</div>\n<div id=\"__sec3\" class=\"sec sec-last\">&nbsp;</div>\n&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p class=\"p p-last\">Category V&nbsp;</p>\n</td>\n<td><strong>Unexpected cardiac arrest</strong> during <strong>intensive care</strong> -</td>\n<td>\n<div id=\"__sec3\" class=\"sec sec-last\">Uncontrolled - transplant team not present or prepared&nbsp; &nbsp;&nbsp;</div>\n&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4464",
      "difficulty": "hard"
    },
    {
      "text": "A 70-year-old man with a known history of DM and HTN on regular medications presents with a history of progressively worsening dyspnoea on exertion. On examination, there is elevated JVP, positive hepatojugular reflux, crackles at the lung bases, hepatomegaly, ascites, and pedal oedemaâ€‹. What is your provisional diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Heart failure"
        },
        {
          "id": 2,
          "text": "Hypertrophic cardiomyopathy"
        },
        {
          "id": 3,
          "text": "Mitral regurgitation"
        },
        {
          "id": 4,
          "text": "Portal hypertension"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given symptoms and signs are suggestive of <strong>heart failure </strong>(Option A).</p>\n<p><strong>Portal hypertension</strong> (Option D) can be a result of r<strong>ight-sided heart failure,</strong> however, the presence of worsening dyspnea along with the other symptoms implies a <strong>primary cardiac condition.</strong></p>\n<p><strong>Heart failure</strong> is a common endpoint for most chronic cardiac conditions such as hypertension, valvular heart disease, and coronary heart disease.<br />The symptoms of heart failure are commonly due to <strong>volume overload </strong>with pulmonary and/or systemic venous pressures.</p>\n<table>\n<tbody>\n<tr>\n<td><strong>RIGHT HEART FAILURE</strong></td>\n<td><strong>LEFT HEART FAILURE</strong></td>\n</tr>\n<tr>\n<td>Symptoms occur due to <strong>systemic congestion</strong></td>\n<td>Symptoms occur due to <strong>pulmonary congestion</strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Raised pulsatile JVP</li>\n<li>Hepatic congestion</li>\n<li>Tender hepatomegaly</li>\n<li>Pitting pedal edema</li>\n<li aria-level=\"1\">Ascites</li>\n<li aria-level=\"1\">Early satiety</li>\n</ul>\n</td>\n<td>\n<ul>\n<li aria-level=\"1\">Shortness of breath</li>\n<li aria-level=\"1\">Orthopnea (dyspnea that occurs within 1-2 mins of lying down)</li>\n<li aria-level=\"1\">Paroxysmal nocturnal dyspnea(shortness of breath that develops after lying down for 30 mins or longer)</li>\n<li aria-level=\"1\">Pulmonary rales</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><br /><br /></p><hr><h3>Related Pearl: Summary of Pathogenesis of Major Findings in Congestive Heart Failure</h3><p><strong>Summary of Pathogenesis of Major Findings in Congestive Heart Failure</strong></p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Abnormality</strong></p>\n</td>\n<td>\n<p><strong>Cause</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Weakness, exercise intolerance, fatigue</p>\n</td>\n<td>\n<p>Left ventricle output inadequate to perfuse muscles; especially, failure of output to rise with exercise</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Ankle, sacral edema</p>\n</td>\n<td>\n<p>Increased peripheral venous pressure &rarr;increased fluid transudation.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hepatomegaly</p>\n</td>\n<td>\n<p>Increased peripheral venous pressure &rarr;increased resistance to portal flow.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Pulmonary congestion</p>\n</td>\n<td>\n<p>Increased pulmonary venous pressure &rarr;pulmonary venous distention and transudation of fluid into air spaces</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Dyspnea on exertion</p>\n</td>\n<td>\n<p>Failure of left ventricular output to rise during exercise &rarr; increased pulmonary venous pressure</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Paroxysmal dyspnea, pulmonary edema</p>\n</td>\n<td>\n<p>Probably a sudden failure of left heart output to keep up with the right heart output &rarr;acute rise in pulmonary venous and capillary pressure &rarr;transudation of fluid into air spaces.</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Orthopnea</p>\n</td>\n<td>\n<p>Normal pooling of blood in lungs in supine position added to the already congested pulmonary vascular system; increased venous return not put out by the left ventricle. (Relieved by sitting up, raising the head of the bed, lying on extra pillows.)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Cardiac dilation</p>\n</td>\n<td>\n<p>Greater ventricular end-diastolic volume.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0882",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is not a radiological finding in a patient with left heart failure?",
      "choices": [
        {
          "id": 1,
          "text": "Kerley b lines"
        },
        {
          "id": 2,
          "text": "Focal oligemia"
        },
        {
          "id": 3,
          "text": "Increased venous blood in lung"
        },
        {
          "id": 4,
          "text": "Change in upper lobe circulation"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Focal oligemia</strong> is <strong>not</strong> a radiological feature of left heart failure. It is seen in <strong>pulmonary embolism</strong> and is also called <strong>Westermark&rsquo;s sign.&nbsp;</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/454e36a125834f768526bc3535d8217cx588x544.PNG\" alt=\"Explanation Image\"><p>It is defined by a <strong>hyperlucent</strong> area with <strong>decreased vascularity </strong>due to oligemia of the involved part of the lung. It is caused by a cutoff of circulation due to an embolus, leading to the loss of visibility of a patch of pulmonary vasculature on an X- ray.&nbsp;</p>\n<p>Radiological signs of <strong>left heart failure </strong>include :</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/ec73a3c622b74d3f9a017192f3f52a65x702x626.PNG\" alt=\"Explanation Image\"><ul>\n<li><strong>Cardiomegaly</strong> - enlargement of the cardiac silhouette (increased cardiothoracic ratio)&nbsp;</li>\n<li>Upper lobe pulmonary venous <strong>congestion</strong> (cephalisation of vessels)&nbsp;</li>\n<li>Interstitial edema.</li>\n<li><strong>Kerley B lines </strong>- horizontal lines in the periphery of the lower posterior lung fields as shown below.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/fe9b0eab4b3046c9a14c85b095fe64c6x424x590.PNG\" alt=\"Explanation Image\"><p>Other radiological signs of Pulmonary embolism :</p>\n<ul>\n<li><strong>Hampton&rsquo;s hump </strong>- a peripheral wedged-shaped density usually located at the pleural base</li>\n<li><strong>Palla&rsquo;s sign </strong>- an enlarged right descending pulmonary artery</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD3075",
      "difficulty": "medium"
    }
  ]
}